NEW YORK, April 22, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Express Scripts Inc. (NASDAQ: ESRX), Incyte Corporation (NASDAQ: INCY), St. Jude Medical Inc. (NYSE: STJ), Novo Nordisk A/S (NYSE: NVO) and Stryker Corp. (NYSE: SYK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1398-100free.

--
Express Scripts Inc. Analyst Notes
On April 15, 2014, Express Scripts Inc. (Express Scripts) announced that it will release its Q1 2014 earnings on April 29, 2014 after the market closes. The Company informed that it has scheduled its quarterly conference call to discuss Q1 2014 results on April 30, 2014, at 8:30 a.m. ET (7:30 a.m. CT). In its Q4 2013 earnings release on February 20, 2014, Express Scripts stated that it expects adjusted earnings per diluted share from continuing operations for Q1 2014 to be between $0.98 and $1.02. According to Zacks Investment Research, the consensus EPS estimate for Q1 2014 is $1.01. The full analyst notes on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/1398-ESRX-22Apr2014.pdf

--
Incyte Corporation Analyst Notes
On April 16, 2014, Delaware-based biopharmaceutical Company, Incyte Corporation (Incyte) announced that it will hold its Q1 2014 financial results conference call at 8:30 a.m. ET on May 1, 2014. The quarterly earnings will be released on May 1, 2014 at 7:00 a.m. ET. According to Zacks investment Research, the consensus loss per share estimate for Q1 2014 is $0.17. The full analyst notes on Incyte are available to download free of charge at:

http://www.analystsreview.com/1398-INCY-22Apr2014.pdf

--
St. Jude Medical Inc. Analyst Notes
On April 16, 2014, St. Jude Medical Inc. (St. Jude Medical) announced its financial results for Q1 FY 2014 (period ended March 29, 2014). The Company reported a 1.9% YoY increase in net sales to $1.4 billion. According to the Company, unfavorable foreign currency translation comparisons decreased Q1 sales by approximately $25 million. On a constant-currency basis, net sales increased by 4% YoY. Net income for Q1 came in at $249.0 million or $0.86 per diluted share. The Company recognized after-tax charges of $25 million, or $0.09 per share, primarily relating to restructuring actions associated with our previously announced organizational changes to combine its operating divisions. As per an article by Wall Street Journal, analysts polled by Thomson Reuters expected EPS of $1.00 and revenue of $1.4 billion. The Company expects its consolidated adjusted net earnings for Q2 to be in the range of $0.99 to $1.01 per share. The full analyst notes on St. Jude Medical are available to download free of charge at:

http://www.analystsreview.com/1398-STJ-22Apr2014.pdf

--
Novo Nordisk A/S Analyst Notes
On April 14, 2014, Novo Nordisk A/S (Novo Nordisk) issued a press release announcing an update on its share repurchase program. As per the press release, as of April 11, 2014, Novo Nordisk has repurchased a total of 13.1 million B shares equal to a transaction value of DKK3.16 billion. Novo Nordisk expects to repurchase B shares for an amount up to DKK15.0 billion during a 12-month period beginning 30 January 2014. The full analyst notes on Novo Nordisk are available to download free of charge at:

http://www.analystsreview.com/1398-NVO-22Apr2014.pdf

--
Stryker Corp. Analyst Notes
On April 15, 2014, Stryker Corp. (Stryker) announced that it has completed its previously announced acquisition of Berchtold Holding AG (Berchtold), a provider of customer-centric healthcare equipment. Berchtold's product portfolio includes surgical tables, equipment booms, and surgical lighting systems geared towards maximizing efficiency and safety in operating rooms and ICUs. As per Stryker, with its existing operating room equipment portfolio, along with Berchtold's product portfolio, the Company will be able to create a comprehensive, quality-focused offering equipped to satisfy a wide range of customer needs around the globe. The Company informed that the transaction is expected to be neutral to Stryker's 2014 EPS excluding acquisition, integration-related and intangible amortization charges. The full analyst notes on Stryker are available to download free of charge at:

http://www.analystsreview.com/1398-SYK-22Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review